Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
MOLN
Molecular Partners AG
Radioactive therapeutics are a central modality (Radio-DARPin) enabling radiopharmaceutical approaches.
|
$136.10M |
N/A
|
|
ACNT
Ascent Industries Co.
Custom manufacturing / contract manufacturing services.
|
$133.96M |
$14.30
-1.99%
|
|
TNXP
Tonix Pharmaceuticals Holding Corp.
TNX-102 SL is Tonix's lead oral small-molecule drug for fibromyalgia (cyclobenzaprine HCl sublingual), a direct product the company develops and plans to bring to market.
|
$132.19M |
$15.06
+7.00%
|
|
SPRO
Spero Therapeutics, Inc.
Tebipenem HBr is an oral small-molecule antibiotic, which is the lead product and central to Spero’s current business focus.
|
$131.12M |
$2.33
-0.21%
|
|
NKTX
Nkarta, Inc.
Nkarta is developing allogeneic CAR NK cell therapy (NKX019) for autoimmune diseases, directly fitting the Cell Therapy product category.
|
$129.97M |
$1.83
+1.38%
|
|
FATE
Fate Therapeutics, Inc.
Fate develops oncology-focused immunotherapies, aligning with Biotech - Oncology.
|
$126.86M |
$1.09
+2.83%
|
|
IXHL
Incannex Healthcare Limited
Incannex develops oral small-molecule therapeutics as fixed-dose drug combinations (IHL-42X).
|
$124.17M |
$0.34
+1.23%
|
|
IMMX
Immix Biopharma, Inc.
Directly categorizes the company’s lead product as a CAR-T cell therapy (cell therapy).
|
$123.99M |
$4.31
+0.23%
|
|
CGTX
Cognition Therapeutics, Inc.
CT1812 (zervimesine) is an orally delivered small-molecule therapeutic, the core product of the company.
|
$121.23M |
$1.66
+13.36%
|
|
IRD
Opus Genetics, Inc.
Core product area: AAV-based gene therapies for inherited retinal diseases (OPGx-LCA5, OPGx-BEST1).
|
$121.01M |
$2.02
+2.27%
|
|
CYBN
Cybin Inc.
Company's pipeline focuses on neuropsychiatric drug development (MDD, GAD) with CYB003/CYB004.
|
$120.61M |
$6.04
-2.11%
|
|
ABOS
Acumen Pharmaceuticals, Inc.
Sabirnetug is a recombinant humanized IgG2 monoclonal antibody targeting soluble AßOs.
|
$118.12M |
$1.96
+1.03%
|
|
BHST
BioHarvest Sciences Inc. Common Stock
BioHarvest operates a CDMO division providing contract development and manufacturing services for plant-based compounds.
|
$116.96M |
$6.92
+1.32%
|
|
ORMP
Oramed Pharmaceuticals Inc.
Oramed's POD platform constitutes the core drug-delivery technology enabling oral administration of therapeutic proteins (e.g., oral insulin).
|
$116.86M |
$2.87
-0.52%
|
|
RANI
Rani Therapeutics Holdings, Inc.
RaniPill is the core drug-delivery platform enabling oral administration of biologics, central to the company's offering.
|
$116.43M |
$1.64
+1.86%
|
|
LPTX
Leap Therapeutics, Inc.
Leap Therapeutics is a biotech company focused on oncology therapies, with lead assets in antibody-based cancer treatments.
|
$116.14M |
$2.04
+367.43%
|
|
IKT
Inhibikase Therapeutics, Inc.
IKT's lead program IKT-001Pro is an oral small-molecule therapeutic prodrug, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$114.76M |
$1.54
-1.59%
|
|
SLGL
Sol-Gel Technologies Ltd.
Proprietary microencapsulation drug-delivery platform is a core technology Sol-Gel uses to formulate topical therapies.
|
$113.35M |
$39.40
-2.45%
|
|
GANX
Gain Therapeutics, Inc.
GT-02287 is a small-molecule therapeutic candidate, aligning with the major product category of oral small-molecule therapeutics.
|
$112.88M |
$3.15
+7.71%
|
|
UNCY
Unicycive Therapeutics, Inc.
Lead programs Oxylanthanum Carbonate (OLC) and UNI-494 are oral small-molecule therapeutics targeting kidney disease and hyperphosphatemia/acute kidney injury.
|
$111.27M |
$6.29
+10.05%
|
|
ENTX
Entera Bio Ltd.
Entera Bio's N-Tab platform is a drug-delivery platform enabling oral administration of large-molecule peptides.
|
$108.68M |
$2.48
-0.40%
|
|
COYA
Coya Therapeutics, Inc.
COYA's autologous regulatory T cell therapy program (COYA 101) represents a direct cell therapy product line.
|
$106.71M |
$6.38
+5.28%
|
|
HLVX
HilleVax, Inc.
Direct vaccine development activity with norovirus vaccine candidates (HIL-216.00) and existing vaccine focus.
|
$104.79M |
$2.09
|
|
ATRA
Atara Biotherapeutics, Inc.
Atara focuses on tab-cel (Ebvallo), an allogeneic T-cell therapy.
|
$104.36M |
$14.96
+2.68%
|
|
INO
Inovio Pharmaceuticals, Inc.
INO's core DNA medicines platform and lead candidate INO-3107 are gene therapy products based on DNA plasmids delivered via CELLECTRA; maps to gene therapy.
|
$104.16M |
$1.97
+8.56%
|
|
RCEL
AVITA Medical, Inc.
RECELL/autologous cell suspension represents a cell-therapy platform within regenerative medicine.
|
$104.08M |
$3.90
+3.87%
|
|
ZNTL
Zentalis Pharmaceuticals, Inc.
Zentalis is a biotech company focused on oncology therapies, centered on cancer indications with their lead asset azenosertib.
|
$103.88M |
$1.45
+0.35%
|
|
EUDA
EUDA Health Holdings Limited
EUDA's core biotech activity is a stem cell platform and cell therapy development using iPSCs.
|
$102.76M |
$2.88
-0.17%
|
|
STTK
Shattuck Labs, Inc.
SL-325 is a monoclonal antibody targeting DR3, making Monoclonal Antibody Therapeutics a direct product category.
|
$102.03M |
$2.13
+6.22%
|
|
CLNN
Clene Inc.
Clene's proprietary clean-surfaced nanotechnology platform operates as a drug delivery platform for CNM-Au8.
|
$101.40M |
$10.12
+7.14%
|
|
CNTX
Context Therapeutics Inc.
The company's pipeline centers on T cell engaging bispecific antibodies (CTIM-76, CT-95, CT-202).
|
$101.37M |
$1.14
+1.79%
|
|
ATOS
Atossa Therapeutics, Inc.
Atossa is a clinical-stage biotech focused on oncology with Z-endoxifen as its lead cancer therapy candidate.
|
$100.73M |
$0.78
+1.61%
|
|
COEP
Coeptis Therapeutics, Inc.
GEAR Cell Therapy Platform is a core cell therapy biotech asset.
|
$98.60M |
$18.84
+6.80%
|
|
ACOG
Alpha Cognition Inc. Common Stock
ZUNVEYL is Alpha Cognition's lead therapeutic targeting Alzheimer's disease.
|
$98.42M |
$6.08
-0.33%
|
|
KBLB
Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories produces recombinant spider silk proteins via transgenic silkworms, a core product category defined as Recombinant Proteins & Enzymes.
|
$97.28M |
$0.09
|
|
PLRX
Pliant Therapeutics, Inc.
Company's lead and mid-stage assets include oral small-molecule therapeutics (bexotegrast and PLN-101095) targeting integrin pathways.
|
$96.99M |
$1.58
+0.64%
|
|
ANEB
Anebulo Pharmaceuticals, Inc.
Cannabis-induced CNS effects relate to neuropsychiatric drug development, aligning with Neuropsychiatric Drug Development.
|
$96.14M |
$2.41
-3.21%
|
Showing page 16 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
